Deep vein thrombosis

Active Ingredient: Bemiparin

Indication for Bemiparin

Population group: only adults (18 years old or older)

The treatment of established deep vein thrombosis, with or without pulmonary embolism, during the acute phase.

For this indication, competent medicine agencies globally authorize below treatments:

5,000-25,000 IU

Route of admnistration


Defined daily dose

5,000 - 25,000 [iU]

Dosage regimen

From 5,000 To 25,000 [iU] once every day

Detailed description

Bemiparin 25,000 IU should be administered by the subcutaneous route at a dose of 115 IU anti-Xa/kg weight, once daily. The recommended duration of treatment is 7±2 days. The daily dose generally corresponds – depending on the body weight range – to the following doses and volumes of the product in prefilled syringes: <50 kg, 0.2 ml (5,000 IU antiXa); 50-70 kg, 0.3 ml (7,500 IU anti-Xa), >70 kg, 0.4 ml (10,000 IU anti-Xa). In patients weighing more than 100 kg body-weight, the dose should be calculated on the basis of 115 IU anti-Xa/kg/day, where the concentration of anti-Xa is 25,000 IU/ml.

In the absence of any contra-indication, oral anticoagulation should be commenced 3-5 days after beginning bemiparin 25,000 IU first administration, and the dose adjusted so as to keep the International Normalized Ratio (INR) value between 2-3 times the control value. Bemiparin administration can be stopped as soon as the said INR value is achieved. Oral anticoagulation should be continued for at least 3 months.

Dosage considerations

When bemiparin is administered subcutaneously, the injection should be given in the subcutaneous cell tissue of the anterolateral or posterolateral abdominal waist, alternately on the left and right sides. The needle should be fully inserted, perpendicularly and not tangentially, into the thick part of a skin fold held between the thumb and the forefinger, the skin fold should be held throughout the whole injection. Do not rub the injection site.

Active ingredient


Bemiparin is a LMWH obtained by depolymerization of heparin from porcine intestinal mucosa. Bemiparin has confirmed its antithrombotic activity and, at the recommended doses, it does not significantly prolong global clotting tests.

Read more about Bemiparin

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.